Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. (“Outset” or the “Company”) (Nasdaq: OM) investors that a class action has been filed on behalf of investors. Outset investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Outset, headquartered in San Jose, California, is a medical technology company whose chief product, the Tablo Hemodialysis System (“Tablo”), is used for the treatment of acute and chronic kidney failure.
The action alleges that, throughout the Class Period, Outset misled investors and/or failed to disclose that: (1) the Company had “continuously made improvements and updates to Tablo over time since its original clearance,” which required further studies and potentially new applications to the U.S. Food and Drug Administration (“FDA”); (2) in the absence of such studies and FDA approval, the Company could not conduct a human factors study on the Tablo pursuant to FDA protocols; and (3) Outset’s inability to conduct the human factors study exposed the Company to the risk of FDA actions, including a shipping hold and marketing suspension, rendering Outset incapable of selling Tablo for home use.
On May 4, 2022, after markets closed, Outset announced disappointing financial results for the first quarter of 2022, which analysts attributed in part to Tablo’s untested performance in the home setting. On this news, the price of Outset common stock fell $16.88, or 2.26% over the next three trading days, from a closing price of $39.94 per share on Wednesday, May 4, 2022, to close at $23.06 per share on Monday, May 9, 2022, on elevated trading volume.
On June 13, 2022, after markets closed, Outset announced that the FDA compelled the Company to suspend all shipments of Tablo for home use until Outset obtained the requisite regulatory clearance. On this news, the price of Outset stock fell $6.95, or 34.05%, from a closing price of $20.41 per share on June 13, 2022, to close at $13.46 per share on June 14, 2022, on extremely heavy trading volume.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
